Discovery
ImmunoPrecise Antibodies Ltd operates globally to offer a continuum of superior antibody services, transforming the face of therapeutic and diagnostic discovery by decreasing turnaround time and risk, and promoting clinical success.
Therapeutics, Diagnostics, & Research
Our elite team has revolutionized antibody discovery. We are the true end-to-end antibody discovery CRO operating from lead characterization, optimization, engineering and in vivo analyses, delivering superior products. We succeed because we have the expertise and experience to provide high-throughput services across the full antibody discovery value chain.
Read more about our end-to-end services
Our elite team has revolutionized antibody discovery. We are the true end-to-end antibody discovery CRO operating from lead characterization, optimization, engineering and in vivo analyses, delivering superior products. We succeed because we have the expertise and experience to provide high-throughput services across the full antibody discovery value chain.
Read more about our end-to-end services
Our next generation of antibody discovery was developed to deliver the most therapeutically relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. We offer proprietary antibody discovery technologies, driven by rigorous computational analyses, feeding our B cell Select™, phage display, and hybridoma generation using semi-solid media and clone picking, to deliver high affinity antibodies. We have the experience with alternative species or strains, including transgenic animals or knock-out strains, and
use our Abthena™ bispecific antibody platform to develop products for your therapeutic pipeline.
Antibodies are also critical tools for the diagnosis of disease. Antibodies recognizing unique antigenic determinants on pathogens, biomarkers, or even an antibody itself (anti-idiotypic) can be developed in multiple species.
In many research areas, the specificity of the antibody binding is highly important–if not critical-for the progress of the research.
At ImmunoPrecise, we offer multiple immunization technologies to deliver poly- or monoclonal antibodies from multi-species, tested in your intended application and delivered in qualities and quantities of your choice.
We pride ourselves on our high customer satisfaction, and our clients have grown accustomed to receiving very thorough and professional services, with a fast turnaround time. We customize programs to generate antibodies that meet each of our clients’ specifications.
B cell Select™
Supported by decades of experience, ImmunoPrecise Antibodies’ B-Cell Select™ platform allows for the interrogation of a greater diversity of an animal’s antibody repertoire than otherwise possible. This proprietary platform is species independent, allowing for the generation of antibodies from samples not possible using other methods. B-Cell Select™, which can develop antibodies from any species (including human) and from any tissue, explores the entire antibody repertoire, and identifies antibodies for anything that is possible in an animal’s immune repertoire including any protein class, complex therapeutic targets, post-translational modifications, and small molecules.
The B-Cell Select platform enables the interrogation of 10 million blood cells to generate native, monoclonal antibodies from immunized animals that specifically target an antigen and allow for the rapid selection of top candidates, drastically increasing the success rate of an antibody discovery program. The platform also harnesses the power of the immune system to generate natural pairing of the antibodies produced by selected B-cells.
Abthena™ Bispecifics
Our proprietary bispecific Abthena™ technology complements our diverse discovery process, integrating seamlessly with our Artemis™ Intelligence Metadata (AIM)™ capabilities, to enable rapid turnaround on additional algorithmic outputs in therapeutic antibody optimization, stability, affinity, and manufacturability.
We have designed an advanced discovery platform for wild-type and fully human bispecific antibody components, which allows for the generation of heterodimer, optimized, IgG backbones with validated binding attributes. Abthena™ produces yields comparable to its monospecific equivalents, with a high degree of dimer formation.
Phage Display
Our phage display approach is based on building custom immune libraries from multiple species, including transgenic animals, or the selection of antigen-specific recombinant antibody fragments from our proprietary human or llama phage libraries. Our proprietary libraries have been made from human patient and naïve (scFv) repertoires, as well as from naïve llama (VHH) repertoires. Custom immune libraries are prepared from blood, spleen, lymph nodes, and bone marrow of immunized animals or humans and capture the entire immune repertoire for panning, rescue, and identification of unique antibodies with pre-specified characteristics.
Transgenics
We are a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. The use of transgenic animals producing fully human idiotypes eliminates the need for a humanization step in the race for a cure. At ImmunoPrecise we successfully apply the transgenic animal of our client’s choice to our hybridoma, B cell Select™ and DeepDisplay™ technologies.
Hybridoma
As leaders in hybridoma development, ImmunoPrecise offers cutting edge antibody development services including, Rapid Prime immunization, DNA immunization (NonaVac™), cell-based immunization (ModiVacc™), electro-fusion and hybridoma generation using semi-solid media and clone picking, as well as high throughput, multiplexed screening methods. With ImmunoProtect™, the DNA sequence of your antibody will be determined and can be used to express your antibody recombinantly.
Humanization
Animal-derived monoclonal antibodies can elicit human anti-animal antibody responses in patients. Therefore, it is usually necessary to replace the animal content with the corresponding human amino acid residues. We provide a robust and efficient antibody humanization service, which consistently retains affinity and specificity levels. Our approach is based on state of the art in silico antibody modeling using our Artemis™ Intelligence Metadata (AIM)™ capabilities to identify essential framework and CDR residues for grafting onto a human antibody framework.
End-to-End Services
We offer multiple, novel immunization platforms as a part of our full-service cycle. Our experience and true end-to-end services let you complete your goals in a fraction of the time, and get you to the finish line faster with better candidates! We work to discover the next generation of antibody therapeutics.
We offer multiple, novel immunization platforms as a part of our full-service cycle. Our experience and true end-to-end services let you complete your goals in a fraction of the time, and get you to the finish line faster with better candidates! We work to discover the next generation of antibody therapeutics.
Target
We know about the importance of the target protein for a successful antibody campaign. Our team of experienced scientists analyzes each target and recommends the best way forward to deliver the product you are looking for. We have developed different strategies to select the correct domains of your target antigen (e.g. in silico modeling) and combine these antigens with the optimized immunization routes in different species. Depending on the characteristics of the individual antigen and the available starting material, we either generate synthetic peptides, recombinant proteins, antibodies or antibody fragments (anti-idiotypic projects), cells lines suitable for immunization (syngeneic or ModiVacc™), or plasmids for genetic immunization (NonaVac™). We further immunize with smaller proteins or whole cell bacteria.
A multitude of immunization technologies is available at ImmunoPrecise, ranging from various injection methods, via dermal tattooing, to live cell-based immunizations.
Peptide Production
The success of your antibody development project is highly dependent on the quality of your antigen. In the case of anti-peptide projects, the immunizing antigen must be of high-purity, enabled for carrier conjugation and safe for injection into animals. Therefore, to help ensure the best start to your antibody development projects, let ImmunoPrecise’s principal scientists directly assist you in epitope prediction and antigen design. Our peptide production service also includes modifications such as phosphorylations.
Recombinant Protein Production
ImmunoPrecise is excited to offer recombinant protein expression and production services. Our proprietary expression technology is designed to deliver fast and large-scale production of (mammalian) recombinant proteins and antibodies for research and pre-clinical applications.
NonaVac™
Our genetic immunization protocols have proven successful in the generation of monoclonal antibodies against new, challenging, and conformation-sensitive targets. It has successfully been applied in transgenic animals.
Through our proprietary vectors, our algorithm-based protocols produce native protein with appropriate post-translational modifications in vivo and provides very high transfection efficiency. We recommend this technology for complex protein classes, including GPCRs and ion channels as it bypasses the requirement to produce difficult to express recombinant proteins, and overcomes conformational obstacles of such antigens. Our in-house developed vectors are not subject to downstream milestones and royalties.
Species Selection
As part of the careful analysis of the target protein our scientific experts will recommend suitable animal species and strains for a successful completion of your project. Most of our technology-platforms are species-agnostic and can be applied to all animals we offer, including a variety of transgenic animals.
ModiVacc™
ModiVacc™ is a proprietary platform to generate high affinity antibodies specific for intractable drug targets such as low immunogenic multiple, membrane-spanning proteins (e.g. GPCRs or ion channels). This highly successful approach has already demonstrated that large panels of antibodies recognizing a broad variety of epitopes can be generated.
The technology is based on the immunization of live ModiVacc™ cells in mice. The ModiVacc™ cell line is a mouse lymphoid tumor cell line containing specific co-factors and is used to stably express the membrane protein of interest. The immunization of live ModiVacc™ cells does result in an initial expansion of the tumor cells in the mice and induces a very strong immune response against the membrane protein-expressing ModiVacc-cells. This immune response ultimately results in the clearance of the expanding tumor cells. Subsequently, monoclonal antibodies can be generated by hybridoma generation using our electro-fusion method, via B cell Select™, or by applying our phage library generation and selection method.
Syngeneic Cell Line
Similar to our ModiVacc™ technology for mice, we offer the immunization of other species with a syngeneic cell line. After the selection of the species for the immunization we discuss a suitable cell line and prepare transfected cells for immunization and screening.
Immunization
ImmunoPrecise is proud to offer multiple, novel immunization platforms as a part of our full-service cycle. We offer a variety of robust and proven immunization methods which can be tailored to the specific project and client’s needs, including genetic immunization (NonaVac™), whole cell immunization (ModiVacc™), dermal tattooing, hydrodynamic tail vein (HTV) and classical injections.
Rapid Prime
ImmunoPrecise’s proprietary Rapid Prime method identifies positive monoclonal antibodies in as little as 32 days. While this method also uses semi-solid media cloning and picking to accelerate the process, it is especially good for generating anti-idiotypic antibodies and has also been extremely useful for generating monoclonal antibodies against conformational epitopes. Other sources of immunogens include conserved or smaller proteins, peptides, and whole cell bacteria.
After the immunization of rodents, we apply our proprietary electrofusion or PEG-fusion to generate hybridomas. The subsequent cloning, using semi-solid media and clone picking, allows us to identify monoclonal antibody producing hybridoma cells in a very short time.
Rapid Prime can also be combined with B cell Select™ or Phage Display.
Transgenics
Currently multiple transgenic rodents are offered to directly generate human antibodies in an animal, eliminating the necessity to humanize the resulting product. At ImmunoPrecise we are proud to have worked with most of the available animals for our clients and partners. We have optimized our suite of services to these rodents and applied our hybridoma, B cell Select™ and phage display technologies successfully.
Phage Display
ImmunoPrecise is pleased to offer in-house and custom phage libraries. Our phage display approach is based on building custom immune libraries from multiple species, or the selection of antigen specific recombinant antibody fragments from our proprietary human or llama phage libraries. Our proprietary libraries have been made from human patient and naïve (scFv) repertoires, as well as from naïve llama (VHH) repertoires. Custom immune libraries are prepared from blood, spleen, lymph nodes, and bone marrow of immunized animals or humans and capture the entire immune repertoire for panning, rescue, and identification of unique antibodies with pre-specified characteristics.
This advanced technology allows us to express antibody fragments in bacteria or rapidly reformat into any given Ig format, such as full-size IgG of various isotypes, bispecifics, Fc mutants to modify effector functions, or chimeras with Fc regions from different species.
B cell Select™
Our proprietary B cell screening, sorting, and sequencing technology increases the speed of antibody discovery, maintains native antibody pairing, provides antibodies of higher sensitivity and specificity and is applicable to any protein class, including complex therapeutic targets. Combining this technology with for example OmniAb® animals offers a truly unique and superior antibody discovery option not found elsewhere.
ModiFuse™
The ModiFuse™ technology is based on our proprietary electrofusion platform for generating larger numbers of hybridomas compared to traditional fusions, which allows for rapid and efficient generation of monoclonal antibodies against virtually any target. This technique is combined with optimized immunization protocols, a wide variety of mouse and rat strains, and semi-automated screening facilities.
DeepDisplay™
A powerful new technology utilizing a combination of Ligand’s OmniAb® transgenic animal platform and ImmunoPrecise Antibodies’ custom phage display antibody selection. DeepDisplay™ Poster
Semi-Solid Media & Clone Picking
ImmunoPrecise uses proprietary semi-solid media to grow mouse and rat hybridomas post-fusion. This special media allows for the support and picking of single cell colonies immediately after the fusion and hybridomas are essentially monoclonal from the start. No serial dilution (limiting dilution) cloning is required. All hybridomas that grow from the fusion are able to be tested for specific antibody within two weeks post-fusion. The quick detection of antibody-specific clones allows for immediate subcloning and cryopreservation of valuable cultures.
Characterization & Optimization
We provide further services to characterize and optimize your valuable monoclonal antibody. Specificity testing in various assays can be complemented with affinity ranking of antibody panels or epitope mapping/binning, using SPR based platforms. After hybridoma sequencing, we can clone, reformat, affinity mature, chimerize, or humanize your antibody before we express the antibody recombinantly at a quality and quantity of your choice.
Antibody Humanization (LucinaTech™)
Animal-derived monoclonal antibodies can elicit human anti-animal antibody responses in patients. Therefore it is usually necessary to replace the animal content with the corresponding human amino acid residues. We provide a robust and efficient antibody humanization service, which consistently retains affinity and specificity levels. Our approach is based on state-of-the-art in silico antibody modeling to identify essential framework and CDR residues for grafting onto a human antibody framework.
Antibody Sequencing
Your monoclonal antibody is extremely valuable, but hybridoma cell lines can become unstable over time and can stop secreting antibody. With ImmunoProtect™, the DNA sequence of your antibody will be determined and can be used to express your antibody recombinantly, should your hybridoma cell line become unstable.
Antibody Chimerization
Our antibody sequencing, cloning, reformatting, and expression service can clone and express any variable antibody domain into any immunoglobulin context required, such as full-size mouse, rabbit, chicken, human format, chimeras with any Fc region of choice, including effector mutants or Fc fusions.
Antibody Characterization
We provide highly purified, well-characterized, low endotoxin, or labeled antibodies for various applications. Additional services include affinity ranking of antibody panels or epitope mapping/binning, using SPR-based platforms, as well as custom assay development.
Antibody Optimization
After antibody sequencing (ImmunoProtect™) further services include reformatting and chimerization. We also provide a robust and efficient antibody humanization (LucinaTech™) service. Our affinity maturation service can complement your antibody optimization.
Antibody Affinity Maturation
Antibody affinity is important in therapeutic and diagnostic applications. ImmunoPrecise’s antibody affinity maturation service can improve antibody affinities by several fold. We apply different strategies to increase the affinity of your antibody, including gene shuffling and random mutagenesis.
Assay Development
ImmunoPrecise offers custom assay development services fully tailored to the needs of our clients. In addition, we have developed assays in-house (e.g. anti-TNF bioactivity assays, CAIA mouse model, etc.). You can find more information on the available assays in our Products section.
Manufacturing
Our proprietary expression technology is designed to deliver fast and large-scale production of (mammalian) recombinant proteins and antibodies for research and pre-clinical applications. Antibodies can be manufactured as hybridoma suspension in a bioreactor, or recombinantly as a transient expression system or with stable cell lines. Our antibody expression platform is developed for rapid and high expression of recombinant antibodies in mammalian cells. Our rPEx technology allows the production of difficult-to-express proteins such as Fc-fusion proteins and bispecific antibodies.
Recombinant Antibody Expression Platform (rAb)
Fully post-translationally modified mammalian recombinant antibodies (rAb’s) are produced via the rAb expression platform. Antibody variable domains can be seamlessly ligated in antibody expression vectors to generate each antibody class.
Gram amounts of purified antibodies with low levels of endotoxin (< 0.05 EU/mg) can be provided in 4 to 6 weeks.
The rAb platform has a modular architecture, thereby allowing several transfection and delivery options.
Recombinant Protein & Antibody Expression
ImmunoPrecise proudly offers a wide range of recombinant protein expression and purification services. Our proprietary expression technology is designed to deliver fast and large-scale production of (mammalian) recombinant proteins and antibodies for research and pre-clinical applications. In addition to custom programs, please visit our catalog for a list of our off-the-shelf products.
Non-Recombinant Purification
ImmunoPrecise’s bioreactor process is an excellent animal-free alternative for custom bulk antibody production. One bioreactor flask can produce as much antibody as ascites from ten to twelve mice. In addition, monoclonal antibody production in bioreactors contains no contaminating host mouse immunoglobulin. We offer a selection of purification procedures for the isolation of specific antibodies from serum, and concentrated tissue culture supernatant. Purified products undergo a full round of analysis to ensure high quality antibody generation for use in important experiments or downstream manufactured products.
Transient protein production platform (rPEx)
Fully post-translationally modified mammalian proteins are produced via the rPEx transient protein production platform. The rPEx production platform consists of serum-free, suspension-growing HEK and CHO cells which are transiently transfected with expression vectors containing the gene of interest. For each recombinant protein to be expressed, several proprietary expression vectors (pUPE expression vectors) are available. Due to the modular architecture, the expression vectors can be easily adapted to meet specific requirements. This allows, for example, the choice of nature and position of the purification tag.
Large amount of recombinant protein can be produced in a very short time span (generally less than 8 weeks). The rPEx platform allows for several transfection and delivery options to match your needs.
Cryostorage
We provide clients with a secure, off-site storage facility to safeguard their assets. We are a trusted partner for the storage of cell lines, tissues, RNA, DNA, plasmid constructs, antibodies, and many other biological materials.